Veracyte, Inc.(VCYT) Intrinsic Value & DCF Analysis (2026)
Current Price
$57.88
Last updated: Jul 24, 2026
Price vs Intrinsic Value
Fundamental Score
Weighted across 6 signals
Narrative Score
No change vs previous
Trend Score
Trend data unavailable
Still researching stocks one at a time?
Intrinziq helps you:
- Turn your stock-picking rules into repeatable strategies
- Find better setups across hundreds of stocks automatically
- Backtest your strategy before putting money to work
The intrinsic value of Veracyte, Inc. (VCYT) is estimated at $53.09 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $57.88, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a 14.38% long-term growth rate and an 11.86% discount rate, reflecting expected future free cash flow and cost of capital.
The intrinsic value of Veracyte, Inc. (VCYT) is estimated at $53.09 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $57.88, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a 14.38% long-term growth rate and an 11.86% discount rate, reflecting expected future free cash flow and cost of capital.Valuation Details
Capital Efficiency
The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.
Fundamental Details
Narrative Details
Trend Details
Investment Coach
Free Cash Flow (in millions)
How Intrinziq Estimates Fair Value
Intrinziq estimates Veracyte, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.
Veracyte, Inc.Healthcare
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.